- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03744403
A Study of CS1001 in Subjects With Advanced Solid Tumors
February 15, 2022 updated by: CStone Pharmaceuticals
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study of an Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- NEXT Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with metastatic or locally advanced unresectable solid tumor, who progressed following treatment with all available standard therapy, or for whom treatment is not available, not tolerated or refused.
- ECOG performance status of 0 or 1.
- Subjects must have at least one measurable lesion.
- Patients with life expectancy ≥ 3 months.
- Subject must have adequate organ function.
- Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after last study drug administration.
Exclusion Criteria:
- Known brain metastasis or other CNS metastasis that is either symptomatic or untreated.
- Subjects with active autoimmune diseases or history of autoimmune diseases should be excluded.
- Patients who have received prior therapies targeting PD-1, PD-L1, or CTLA-4.
- Known history of HIV infection.
- Subjects with active Hepatitis B or C infection.
- Any unresolved CTCAE Grade ≥ 2 toxicities from prior anti-cancer therapy with the exception of vitiligo, alopecia.
- Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma.
- Known history of alcoholism or drugs abuse.
- Subjects who received organ transplantation.
- Known psychiatric disorders that would interfere with cooperation with the requirements of the trial.
- Female subjects who are pregnant or breast-feeding; Male or female subjects of childbearing potential who refuse to use an effective method of birth control.
For more information regarding trial participation, please contact at cstonera@cstonepharma.com
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CS1001 monoclonal antibody
|
In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
In the dose-expansion part, both dose levels will be expanded.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: From first dose to 90 days after last dose of CS1001, up to 2 years
|
From first dose to 90 days after last dose of CS1001, up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 4, 2018
Primary Completion (ACTUAL)
October 31, 2020
Study Completion (ACTUAL)
July 21, 2021
Study Registration Dates
First Submitted
November 14, 2018
First Submitted That Met QC Criteria
November 14, 2018
First Posted (ACTUAL)
November 16, 2018
Study Record Updates
Last Update Posted (ACTUAL)
February 16, 2022
Last Update Submitted That Met QC Criteria
February 15, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS1001-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
Clinical Trials on CS1001
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCStone PharmaceuticalsRecruitingAdvanced Solid TumorChina
-
CStone PharmaceuticalsCompletedRelapsed Small Cell Lung CancerChina
-
CStone PharmaceuticalsCompletedHodgkin LymphomaChina
-
CStone PharmaceuticalsCompletedExtranodal Natural Killer/T-Cell LymphomaUnited States, China
-
CStone PharmaceuticalsCompleted
-
CStone PharmaceuticalsBayerCompletedAdvanced Refractory Solid TumorsAustralia
-
CStone PharmaceuticalsCompletedNon-Small Cell Lung Cancer Stage IIIChina
-
CStone PharmaceuticalsBlueprint Medicines CorporationCompletedHepatocellular CarcinomaChina
-
CStone PharmaceuticalsActive, not recruitingNon Small Cell Lung CancerChina
-
CStone PharmaceuticalsCompletedGastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaChina